EEOICPA Compensation Results (through March

2004)

Russ Henshaw, MSEpidemiologist

NIOSH/Office of CompensationAnalysis & Support

Cincinnati, OH

Completed Claim Results:Important Caveats

Results are through March 31, 2004 Includes only those cases in which

NIOSH has received notice from DOL of an official compensation decision (~ 2/3 of cases)

May NOT be predictive of future results Unless otherwise noted, results are for

claims with only one primary cancer

Completed Claims: Proportion That Were Compensable, by NIOSH-IREP Cancer Model

Cancer Model (ICD-9 Code)

Total

Compensated

Oral Cavity and Pharynx (140-149)

23 4 (17%)

Esophagus (150) 19 0 (0%)

Stomach (151) 21 0 (0%)

Colon (153) 78 1 (1%)

Rectum (154) 27 0 (0%)

Completed Claims: Proportion That Were Compensable, by

NIOSH-IREP Cancer Model (Cont.)

Cancer Model (ICD-9 Code)

Total

Compensated

All digestive (150-159) 3 0 (0%)

Liver (155.0) 7 5 (71%)

Gallbladder (155.1, 156) 3 1 (33%)

Pancreas (157) 43 0 (0%)

Lung (162) 230 209 (91%)

Completed Claims: Proportion That Were Compensable, by

NIOSH-IREP Cancer Model (Cont.)

Cancer Model (ICD-9 Code)

Total

Compensated

Other respiratory (160, 161, 163-165)

19 6 (32%)

Bone (170) 3 1 (33%)

Connective tissue (171) 13 0 (0%)

Malignant melanoma (172) 19 3 (16%)

Non-melanoma skin-Basal Cell (173)

25 11 (44%)

Completed Claims: Proportion That Were Compensable, by

NIOSH-IREP Cancer Model (Cont.)

Cancer Model (ICD-9 Code)

Total Compensated

Non-melanoma skin-Squamous Cell (173)

16 1 (6%)

Breast (174-175) 69 1 (1%)

Ovary (183) 2 0 (0%)

Female genitalia, excluding ovary (179-182, 184)

14 0 (0%)

All male genitalia (185-187) 219 0 (0%)

Completed Claims: Proportion That Were Compensable, by

NIOSH-IREP Cancer Model (Cont.)

Cancer Model (ICD-9 Code)

Total

Compensated

Bladder (188) 42 2 (5%)

Urinary organs, excluding bladder (189)

11 5 (45%)

Eye (190) 2 0 (0%)

Nervous system (191-192) 33 0 (0%)

Thyroid (193) 14 0 (0%)

Completed Claims: Proportion That Were Compensable, by

NIOSH-IREP Cancer Model (Cont.)

Cancer Model (ICD-9 Code)

Total Compensated

Other endocrine glands (194) 2 0 (0%)

Other and ill-defined sites (195) 0 N/ALymphoma & multiple myeloma (200-203)

90 2 (2%)

Leukemia, excluding CLL (204-208, excluding 204.1)

6 5 (83%)

Acute Lymphocytic Leukemia (204.0)

3 3 (100%)

Completed Claims: Proportion That Were Compensable, by

NIOSH-IREP Cancer Model (Cont.)

Cancer Model (ICD-9 Code)

Total

Compensated

Acute Myeloid Leukemia (205.0) 8 3 (38%)

Chronic Myeloid Leukemia (205.1)

7 5 (71%)

Claims with unknown primary cancer

28 24 (86%)

Claims with multiple primary cancers

226 146 (65%)

All Completed Claims 1325

438 (33%)

Compensability Rate, by Cancer Model (10 or More Completed

Cases)91%

45%32%

17% 16%

44%

0%10%20%30%40%50%60%70%80%90%

100%

Compensability Rate, by Cancer Model (10 or More Completed

Cases)

6% 5% 1% 1%2%0%

10%20%30%40%50%60%70%80%90%

100%

SCC Bladder Lym &MM

Breast Colon

Compensability Rate, by Cancer Model (10 or More Completed

Cases) 0% (no compensable cases):

Esophagus Stomach Rectum Pancreas Connective tissue Female genitalia, excluding ovary All male genitalia Nervous system Thyroid

Compensability Rates for “Unknown Primary” and “Multiple

Primary” Claims86%

65%

0%10%20%30%40%50%60%70%80%90%

100%

Unknown Primary Multiple Primary

Proportion of Claims That Were Compensable, by Years Worked

10%15%

40%

50%

29%

0%

10%

20%

30%

40%

50%

60%

<10Years

10-19Years

20-29Years

30-39Years

40+Years

Proportion of Claims That Were Compensable, by Age at

Diagnosis

0%

10%

22%28%

34%

54%

14%

0%

10%

20%

30%

40%

50%

60%

Aged20-29

Aged30-39

Aged40-49

Aged50-59

Aged60-69

Aged70-79

Aged80+

Lung Cancer Compensability (Single Primary Cancer) by

Smoking Status86%

91%

0%10%20%30%40%50%60%70%80%90%

100%

Never Smoked Ever Smoked

Lung Cancer Compensability (Single Primary Cancer) by

Smoking Status86%

95% 92%

75%

50%

100%91%

0%10%20%30%40%50%60%70%80%90%

100%

Compensability Rate by Gender (All Completed

Claims)

37%

4%

0%10%20%30%40%50%60%70%80%90%

100%

Males Females

Summary Some initial surprises, but current results

are skewed: By dose reconstruction “efficiency process” Possibly by incomplete data (we are awaiting

official decisions from DOL for about 1/3 of all completed cases)

Data will continue to be monitored for trends & anomalies

Results are not predictive of future claims